Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BLUR (BLUR) fluctuates 43.5% in 24 hours: trading volume surges over 3000% driven by buying influx

BLUR (BLUR) fluctuates 43.5% in 24 hours: trading volume surges over 3000% driven by buying influx

Bitget PulseBitget Pulse2026/04/02 01:24
Show original
By:Bitget Pulse

Volatility Brief

In the past 24 hours, BLUR's price rebounded from a low of $0.0194 to a high of $0.02783, currently quoted at $0.0219, with a volatility amplitude of 43.5%. Trading volume surged significantly, reaching $162 million to $227 million, an increase of over 3200% compared to the previous day. The peak spot trading volume was $175 million.

Analysis of Reasons for Abnormal Fluctuations

- Explosive growth in trading volume: Spot trading volume soared by 674%, driving the price quickly from $0.0191 to above $0.0241.

- Active holder dynamics: Top holder proportion decreased by 13.3% (from 15% to 13%), and more than 557 new holders entered, showing that retail buying dominated.

- No official announcement or major on-chain events, only signs of market breakout and accumulation (such as whales hinting at accumulation) amplified the volatility.

Market Views and Outlook

The mainstream sentiment in the community is bullish, with traders frequently giving long signals (such as longing from $0.0199, targeting $0.027), emphasizing that maintaining above $0.022 could continue the rise, but warning of short-term pullback risks to fill the FVG gap ($0.0226-$0.0236). Analysts predict that a breakthrough above $0.026 could extend the upward trend; otherwise, it may test the $0.0219 support.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for information reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23